G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
G1 Therapeutics (GTHX) Misses Q3 EPS by 1c; Offers FY23 COSELA Sales Guidance
November 1, 2023 6:33 AM EDTG1 Therapeutics, Inc. (NASDAQ: GTHX) reported Q3 EPS of ($0.35), $0.01 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $14.24 million.
The Company expects to generate between $44 million and $47 million in COSELA net revenue in... More
